RxDoctor Payments DataLook up a doctor →

Jennifer Miley, MD

Family Practice · Pensacola, FLNPI 1154338424

Payments from drug & device makers

$7,012in general payments, 2019–2025

Across 409 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$655
  • Amgen$467
  • Novo Nordisk$441
  • Lilly USA, LLC$417
  • AstraZeneca$352
  • plus $4K from 43 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$6,78197%
  • Education$2163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,012 in reported general payments places this provider in the 95th percentile of 429 family practice providers in Florida.

See all family practice providers in Florida

Medicare billing

Part B allowed, 2024
$510,568
Medicare patients
601
Services billed
17,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$182,669
MounjaroTirzepatide106$153,811
EliquisApixaban119$133,175
FarxigaDapagliflozin Propanediol38$52,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$44,792
TrulicityDulaglutide30$33,033
RybelsusSemaglutide21$31,735
JardianceEmpagliflozin17$27,373
VraylarCariprazine Hcl16$22,649
MyrbetriqMirabegron18$16,533
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$9,486
Rosuvastatin Calcium564$7,713
Tresiba Flextouch U-100Insulin Degludec17$6,763
Lidocaine11$5,213
Gabapentin207$4,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$441$214,404157 claims
Lilly USA, LLCMounjaro, Trulicity$417$186,844136 claims
PfizerEliquis$655$133,175119 claims
AstraZenecaFarxiga$352$52,39638 claims
GSKTrelegy Ellipta$266$44,79248 claims
Boehringer IngelheimJardiance$226$27,37317 claims
AbbVieVraylar, Synthroid$1,016$25,09162 claims
Astellas Pharma US IncMyrbetriq$333$16,53318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 family practice providers in Florida.

Other family practice in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →